NASDAQ:CLLS

Cellectis Stock Forecast, Price & News

$33.09

-0.16 (-0.48 %)

(As of 01/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$33.09

Now: $33.09▼

$34.71

50-Day Range

$25.86

MA: $29.02▼

$33.25

52-Week Range

$7.32

Now: $33.09▼

$34.71

Volume602,156 shs

Average Volume458,233 shs

Market Capitalization$1.41 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.59

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.

MarketRank^™

Overall MarketRank^™

0.83 out of 5 stars

Medical Sector

1098th out of 1,928 stocks

Biological Products, Except Diagnostic Industry

139th out of 177 stocks

1.3 Analyst's Opinion

Consensus Rating
Cellectis has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $27.20, Cellectis has a forecasted downside of 17.8% from its current price of $33.09.
Amount of Analyst Coverage
Cellectis has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Cellectis has received 380 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cellectis has received 269 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cellectis has received 58.55% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote “Outperform” if you believe CLLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cellectis does not currently pay a dividend.
Dividend Growth
Cellectis does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellectis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 16.41% of the stock of Cellectis is held by insiders.
Percentage Held by Institutions
Only 33.30% of the stock of Cellectis is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Cellectis are expected to decrease in the coming year, from ($1.96) to ($1.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellectis is -17.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellectis is -17.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cellectis has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CLLS

Previous Symbol

CUSIPN/A

CIK1627281

Webwww.cellectis.com

Phone33-1-81-69-16-00

Employees253

Debt

Debt-to-Equity Ratio0.10

Current Ratio6.11

Quick Ratio6.00

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$22.99 million

Price / Sales61.15

Cash FlowN/A

Price / Cash FlowN/A

Book Value$8.37 per share

Price / Book3.95

Profitability

EPS (Most Recent Fiscal Year)($2.41)

Net Income$-102,090,000.00

Net Margins-110.52%

Return on Equity-23.56%

Return on Assets-16.69%

Miscellaneous

Outstanding Shares42,486,000

Market Cap$1.41 billion

Next Earnings Date3/3/2021 (Estimated)

OptionableOptionable

$33.09

-0.16 (-0.48 %)

(As of 01/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

How has Cellectis' stock been impacted by Coronavirus?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLLS stock has increased by 189.5% and is now trading at $33.09.
View which stocks have been most impacted by COVID-19.

Is Cellectis a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cellectis stock.
View analyst ratings for Cellectis or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cellectis?

Wall Street analysts have given Cellectis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cellectis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Cellectis' CEO?

1,428 employees have rated Cellectis CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Cellectis' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Cellectis.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) released its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.69) by $0.02. The biotechnology company had revenue of $9.24 million for the quarter, compared to the consensus estimate of $2.25 million. Cellectis had a negative net margin of 110.52% and a negative return on equity of 23.56%.
View Cellectis' earnings history.

What price target have analysts set for CLLS?

6 analysts have issued 1-year target prices for Cellectis' stock. Their forecasts range from $11.00 to $39.00. On average, they expect Cellectis' share price to reach $27.20 in the next year. This suggests that the stock has a possible downside of 17.8%.
View analysts' price targets for Cellectis or view Wall Street analyst' top-rated stocks.

Who are some of Cellectis' key competitors?

Some companies that are related to Cellectis include Vir Biotechnology (VIR), Relay Therapeutics (RLAY), China Biologic Products (CBPO), Editas Medicine (EDIT), Allogene Therapeutics (ALLO), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Kymera Therapeutics (KYMR), bluebird bio (BLUE), NanoString Technologies (NSTG), Revolution Medicines (RVMD), AlloVir (ALVR), Sorrento Therapeutics (SRNE) and Sangamo Therapeutics (SGMO).
View all of CLLS's competitors.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

Who are Cellectis' key executives?

Cellectis' management team includes the following people:

Dr. David J. D. Sourdive, Co-Founder, Exec. VP of Strategic Initiatives & Director (Age 53, Pay $452.66k)
Mr. Eric Dutang, Chief Financial Officer (Age 46)
Mr. Jean Charles Epinat, Chief Technological Officer
Mr. Stephan Reynier, Chief Regulatory & Compliance Officer (Age 51)
Ms. Marie-Bleuenn Terrier, Gen. Counsel (Age 38)
Ms. Jennifer Moore, Sr. VP of PR
Ms. Kyung Nam-Wortman, Exec. VP & Chief HR Officer
Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 57)
Simon Harnest, Sr. VP of Corp. Strategy & Fin.

When did Cellectis IPO?

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.14%) and OneAscent Financial Services LLC (0.06%).

Which institutional investors are buying Cellectis stock?

CLLS stock was purchased by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and OneAscent Financial Services LLC.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $33.09.

How big of a company is Cellectis?

Cellectis has a market capitalization of $1.41 billion and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 253 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here